ADiTx Therapeutics logo
ADiTx Therapeutics ADTX
$ 0.88 -3.3%

Quarterly report 2025-Q2
added 08-14-2025

report update icon

ADiTx Therapeutics Balance Sheet 2011-2026 | ADTX

Annual Balance Sheet ADiTx Therapeutics

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

287 K 1.94 M 203 K - -8.66 M 162 K 47.9 K -25 K - - - - - -

Long Term Debt

436 K 1.04 M 1.89 M - - - - - - - - - - -

Long Term Debt Current

683 K 1 M 1.09 M - 391 K - - - - - - - - -

Total Non Current Liabilities

- - - - 858 K - - 25 K - - - - - -

Total Current Liabilities

23.4 M 25.9 M 3.64 M 3.61 M 1.23 M - - - - - - - - -

Total Liabilities

23.9 M 28.5 M 5.53 M 6.48 M 2.09 M 2.98 M 1.65 M 84.9 K - - - - - -

Retained Earnings

-168 M -128 M -95 M -67.4 M -20.9 M -11.7 M -5.9 M -213 K - - - - - -

Total Assets

32.1 M 44.6 M 10.7 M 16.7 M 13.1 M 124 K 116 K 25 K - - - - - -

Cash and Cash Equivalents

833 K 97.1 K 2.77 M 7.87 M 10.5 M 4.09 K - - - - - - - -

Book Value

8.29 M 16 M 5.21 M 10.2 M 11 M -2.85 M -1.54 M -59.9 K - - - - - -

Total Shareholders Equity

497 K 16.1 M 5.21 M 10.2 M 11 M -2.85 M - - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet ADiTx Therapeutics

2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

113 K 277 K 436 K 592 K 745 K 892 K 1.04 M 1.2 M 1.42 M - 1.89 M - - - 5 2.77 M 2.96 M 779 K 858 K 865 K 858 K 858 K - - - - - - - 35 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

20.7 M 15.5 M 23.9 M 25.4 M 22 M 18.2 M 28.5 M 12.4 M 11.2 M 7.57 M 5.53 M 6.49 M 9.38 M 7.07 M 6.48 M 6.61 M 9.94 M 6.65 M 2.09 M 2.09 M 2.09 M 2.09 M 2.98 M 2.98 M 2.98 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-181 M -174 M -168 M -163 M -150 M -142 M -128 M -117 M -107 M -101 M -95 M -86.8 M -79.3 M -73.4 M -67.4 M -43.3 M -33.4 M -27.3 M -20.9 M -20.9 M -20.9 M -20.9 M -11.7 M -11.7 M -11.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

32.7 M 31.2 M 32.1 M 29.8 M 28.4 M 28 M 44.6 M 8.23 M 7.29 M 7.63 M 10.7 M 19.2 M 10.7 M 11.8 M 16.7 M 19.6 M 15.9 M 18 M 13.1 M 13.1 M 13.1 M 13.1 M 124 K 124 K 124 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

324 K 476 K 833 K 329 K 91.2 K 88.7 K 97.1 K 1.65 M 96 K 303 K 2.77 M 9.24 M 804 K 2.12 M 7.87 M 5.47 M 8.61 M 14 M 10.5 M 10.5 M 10.5 M 10.5 M 4.09 K 4.09 K 4.09 K - 116 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

12 M 15.8 M 8.29 M 4.45 M 6.34 M 9.78 M 16 M -4.22 M -3.87 M 68.1 K 5.21 M 12.7 M 1.36 M 4.72 M 10.2 M 13 M 5.96 M 11.4 M 11 M 11 M 11 M 11 M -2.85 M -2.85 M -2.85 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

13 M 16.6 M 497 K 4.71 M 6.34 M 9.78 M 16.1 M -4.22 M -3.87 M 68.1 K 5.21 M 12.7 M 1.36 M 4.72 M 10.2 M 13 M 5.96 M 11.4 M 11 M 11 M 11 M 11 M -2.85 M -2.85 M -2.85 M -1.81 M -1.54 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of ADiTx Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 19.53 -0.2 % $ 913 M usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 14.67 -0.07 % $ 6.09 B irlandaIrlanda
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 2.82 1.44 % $ 283 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Editas Medicine Editas Medicine
EDIT
$ 2.32 - $ 206 M usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 1.09 -9.17 % $ 22.4 M israelIsrael
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 23.45 -1.64 % $ 631 M usaUSA
EyePoint Pharmaceuticals EyePoint Pharmaceuticals
EYPT
$ 13.06 0.08 % $ 957 K usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 2.85 3.26 % $ 592 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Equillium Equillium
EQ
$ 2.06 - $ 118 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.29 -3.01 % $ 329 M britainBritain
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
$ 27.44 -0.54 % $ 1.58 B usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Heron Therapeutics Heron Therapeutics
HRTX
$ 0.83 3.62 % $ 138 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
$ 0.18 2.33 % $ 3.55 M irlandaIrlanda
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Johnson & Johnson Johnson & Johnson
JNJ
$ 239.24 -0.29 % $ 576 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Kala Pharmaceuticals Kala Pharmaceuticals
KALA
$ 0.2 -6.67 % $ 759 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 47.55 0.98 % $ 4.28 B schweizSchweiz